Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

The Gavin and Stacey star has come to the realisation that ‘nothing about my eating has anything to do with being hungry’ ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

Since being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United ...

Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...

BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug developer said on Wednesday.